A Retrospective Look at Progress
to Date and New Directions in
2020 and Beyond
If we could locate points on a compass serving as a metaphor for future directions in kidney cancer management, the directions most likely would turn toward combination therapies, biomarkers, precision medicine, and innovative treatment approaches. There are numerous points in between arising from the unmet need to explore a myriad of different directions—all of which provided touchstones for discussion at the recently held 18th International Kidney Cancer Symposium in Miami, November 15-16, attracting more than 400 attendees. This was one of the largest crowds to attend the IKCS, sponsored by the Kidney Cancer Association. Two international symposia are held each year, the second scheduled for Antwerp, Belgium in 2020.
I had the pleasure and honor to serve as one of 80 speakers at the scientific sessions as key opinion leaders and investigators presented, analyzed, debated, and looked toward some consensus on numerous issues in a program ranging across the broadest possible spectrum of topics on renal cell carcinoma offered at any meeting worldwide. And yet, as broad as that spectrum was, there are a handful of overarching concerns that still dominate the narrative—among them the four mentioned at the beginning of my message.
During the last year, for example, two major approvals of combination therapies have provided compelling evidence for changing the paradigm of first-line therapy. (continue)
Revisiting IL-2 Therapy in Renal Cell Carcinoma: A Case Report of a Patient Treated With Pegylated IL-2, Bempegaldesleukin (NKTR-214)
Elshad Hasanov, MD, PhD and
Nizar M. Tannir, MD, FACP
Department of Genitourinary Medical Oncology
Division of Cancer Medicine
MD Anderson Cancer Center
Houston, TX Read
Essential Peer-Reviewed Reading
in Kidney Cancer
The peer-reviewed articles summarized in this section were selected by the Editor-in-Chief, Robert A. Figlin, MD, for their timeliness, importance, relevance,and potential impact on clinical practice or translational research.
Outcomes of Patients with Metastatic Renal Cell Carcinoma Treated with Targeted Therapy After Immuno-oncology Checkpoint Inhibitors. Graham , Shah AY, Wells JC, et al. Eur Urol Oncol. 2019 Nov 27. pii: S2588-9311(19)30160-9. doi: 10.1016/j.euo.2019.11.001. [Epub ahead of print]
Summary: Among 314 patients, 276 (87.9%) and 38 (12.1%) were treated with VEGFR-TKI and mTORI therapy, respectively. The most common tyrosine kinase inhibitor treatments were axitinib, cabozantinib, and sunitinib following IO therapy. In adjusted models, patients treated with VEGFR-TKI versus mTORI therapy had lower hazard of TTD after IO treatment (aHR=0.46; 95% CI: 0.30-0.71; P < 0.01).
Newsworthy, late-breaking information from Web-based sources, professional societies, and government agencies
Highlights from the IKCS, Miami, November 14-16: New Data on Combination Therapy, Potential Strategy in Refractory RCC, and Brain Mets
More than 400 attendees gathered in Miami for the 18th International Kidney Cancer Symposium, as key opinion leaders presented emerging and pivotal data from an agenda representing the most comprehensive information available on kidney cancer. Selected highlights are covered here. Detailed results and perspectives on the scientific symposium are available on the Kidney Cancer Association website.
To view slides of all presenters, please visit: http://www.euikcs.com/kca/miami2019
To view videos of all presentations, please visit:
https://www.oncologytube.com/channel/kidneycancer
Survival Outcome of Pazopanib and Sunitinib as
First-line Targeted Therapy in Metastatic Renal Cell Carcinoma
A ‘real world’ retrospective review of practice in a tertiary cancer center in the North-West of England
1,3
1,2
1
2
1,2
1,2
1
2
3The Clatterbridge Cancer Centre, Wirral, United Kingdom
Read